MAA
ADMA icon

Mraz Amerine & Associates’s ADMA Biologics ADMA Stock Holding History

Mraz Amerine & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
+17,700
New +$161K 0.02% 186

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mraz Amerine & Associates's ADMA Position: Q2 2026 in Review

Mraz Amerine & Associates opened a new position in ADMA Biologics (ADMA) in Q2 2026: 17,700 shares worth $148K. The stake represents 0.02% of the portfolio and ranks #186 among its holdings.

322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Mraz Amerine & Associates held 17,700 shares of ADMA Biologics worth $148K as of Q2 2026.
  • ADMA Biologics was a new Mraz Amerine & Associates position in Q2 2026.
  • ADMA Biologics made up 0.02% of Mraz Amerine & Associates's portfolio in Q2 2026, its #186 holding.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Mraz Amerine & Associates's 13F filing for Q2 2026, filed 16 Jul 2026.